Analysis of Voglibose by Post-Column Derivatization Method

Significance of the Topic

Voglibose is an α-glucosidase inhibitor widely used to manage postprandial blood glucose levels in diabetic patients. Because it lacks chromophoric groups, direct UV detection is not feasible, making sensitive and reliable analytical methods essential for quality control and regulatory compliance in pharmaceutical manufacturing.

Objectives and Study Overview

This study implemented the Japanese Pharmacopoeia 17th Edition monograph assay for voglibose tablets using Shimadzu’s Nexera™ lite HPLC system with post-column fluorescence derivatization. Key objectives included verifying system suitability, evaluating linearity and sensitivity, and demonstrating the method’s reproducibility under pharmacopeial conditions.

Methodology and Instrumentation

• Chromatographic System: Nexera™ lite HPLC equipped with Shim-pack™ GIST NH2 column (150 mm × 4.0 mm I.D., 5 µm).
• Mobile Phase: Sodium phosphate buffer (pH 6.5) and acetonitrile (300:600).
• Flow Rate and Temperature: 0.37 mL/min, column at 25 °C, injection volume 50 µL.
• Post-Column Derivatization: Taurine/sodium periodate reagent delivered via Shimadzu’s CRB-40 reaction box at 100 °C; reagent flow 0.37 mL/min.
• Detection: RF-20AXS fluorescence detector (Ex. 350 nm, Em. 450 nm) with cell temperature controlled at 15 °C, eliminating need for external cooling chamber.
• Software: LabSolutions workstation ensuring full data integrity compliance.

Main Results and Discussion

• System Suitability: Resolution between lactose and voglibose was 5.2 (JP criterion ≥ 4); peak area %RSD was 0.13% (n = 6, JP criterion ≤ 2%).
• Linearity: Calibration over 25–1000 µg/L exhibited an r2 of 0.99995, confirming excellent linear response.
• Sensitivity and Repeatability: At a low concentration of 25 µg/L, the peak area RSD was 1.1% (n = 6), demonstrating high sensitivity and precision.
• Workflow Efficiency: The integrated temperature control removed the need for a separate cooling chamber, simplifying system setup.

Benefits and Practical Applications

• Full compliance with JP 17th Edition requirements for assay performance and reproducibility.
• High throughput and robust quantitation of voglibose in tablet formulations.
• Data integrity assured via LabSolutions, meeting regulatory standards for pharmaceutical QC.
• Elimination of additional cooling hardware enhances laboratory efficiency.

Future Trends and Opportunities

Emerging developments may include miniaturized and automated derivatization modules, broader application to other non-chromophoric drugs, and integration with advanced data analytics. Improvements in detector sensitivity and inline sample preparation will further enhance throughput and compliance with evolving pharmacopeial standards.

Conclusion

The Shimadzu Nexera™ lite HPLC system with post-column fluorescence derivatization reliably fulfills the JP 17th Edition assay for voglibose tablets. It offers robust system performance, excellent linearity, and high sensitivity without requiring external cooling, making it an effective solution for pharmaceutical quality control environments.